Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dictamnus root bark, also known as Cortex Dictamni or Bai Xian Pi, is the dried root bark of Dictamnus dasycarpus Turcz. or Dictamnus albus L. (family Rutaceae). It is a cornerstone of Traditional Chinese Medicine (TCM) widely utilized for its heat-clearing, dampness-drying, wind-dispelling, and antipruritic properties. The herb is primarily indicated for inflammatory and allergic skin conditions, including atopic dermatitis (eczema), psoriasis, urticaria, seborrheic dermatitis, and generalized pruritus, as well as damp-heat jaundice and rheumatoid arthritis. Phytochemical studies have identified furoquinoline alkaloids (such as dictamnine, skimmianine, and γ-fagarine) and limonoids (such as obacunone, limonin, and fraxinellone) as its primary bioactive constituents. These compounds exert anti-inflammatory, anti-allergic, and antimicrobial effects by modulating key molecular targets, including MRGPRX2, NR1D1, c-Met, NRF2, MIF, MAPK1, and PINK1. Dictamnus root bark is typically administered orally as a decoction or concentrated granules, or applied topically in creams and washes.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on dictamnus root bark.
Work on dictamnus root bark? Claim this page to correct or add information. Claim this page